Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADM2 | Q7Z4H4 | 9/20 | 0.48 |
| ▸ | CALCRL | Q16602 | 10/20 | 0.47 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.47 |
| ▸ | CALCB | P10092 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31039423 | 0.78 | ADM2 (0.52) | ADM2CALCRLRAMP1CALCB | |
| SCHEMBL846711 | 0.77 | CALCRL (0.47) | ADM2CALCRLRAMP1CALCB | |
| SCHEMBL846709 | 0.76 | CALCRL (0.49) | ADM2CALCRLRAMP1CALCBALDH1A1 | |
| SCHEMBL846259 | 0.76 | CALCA (0.47) | ADM2CALCRLRAMP1CALCB | |
| SCHEMBL17881436 | 0.76 | CALCA (0.47) | ADM2CALCRLRAMP1CALCB | |
| SCHEMBL846283 | 0.76 | CALCRL (0.46) | ADM2CALCRLRAMP1CALCB | |
| SCHEMBL836905 | 0.75 | CALCRL (0.49) | ADM2CALCRLRAMP1CALCB | |
| SCHEMBL16508720 | 0.75 | MAPT (0.51) | CALCRLRAMP1ALDH1A1 | |
| SCHEMBL16508817 | 0.74 | CALCRL (0.48) | ADM2CALCRLRAMP1CALCB | |
| SCHEMBL13272676 | 0.74 | CALCRL (0.48) | ADM2CALCRLRAMP1CALCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143266-B2 | Aryl heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143266-B2 | Aryl heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100120809-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
| US-20100120809-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
| WO-2008130524-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120809-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CCKBR | ADM2 145/4885CALCRL 4/4885RAMP1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.